Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories
09:30am, Monday, 24'th Nov 2025
MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences�
The shortened holiday week is here, and the futures are trading higher this morning.
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights
06:25am, Saturday, 22'nd Nov 2025
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of E
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
06:45pm, Thursday, 20'th Nov 2025
Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Exact Sciences Corporation (NASDAQ: EXAS)
05:30pm, Thursday, 20'th Nov 2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
Exact Sciences Corporation (EXAS) M&A Call Transcript
05:03pm, Thursday, 20'th Nov 2025
Exact Sciences Corporation ( EXAS ) M&A Call November 20, 2025 9:00 AM EST Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President &
Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More
04:44pm, Thursday, 20'th Nov 2025
Markets were broadly lower on Thursday, giving up early gains as excitement about Nvidia's latest financial results gave way to worries about the future. PACS Group and Exact Sciences led gainers on t
Why Exact Sciences Rallied Over 50% This Week
03:31pm, Thursday, 20'th Nov 2025
Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)
03:13pm, Thursday, 20'th Nov 2025
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“E
Why Exact Sciences Stock Surged Today
03:01pm, Thursday, 20'th Nov 2025
Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer.
Is it too late to buy Exact Sciences stock after Abbott's $21B deal?
01:29pm, Thursday, 20'th Nov 2025
Exact Sciences (NASDAQ: EXAS) rallied nearly 20% on November 20 after Abbott Laboratories (NYSE: ABT) announced a $21 billion all-cash deal to acquire the molecular diagnostics company.
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More
01:26pm, Thursday, 20'th Nov 2025
Major U.S. equities indexes turned lower Thursday afternoon, reversing early gains as a rally powered by Nvidia's (NVDA) blockbuster earnings after the bell Wednesday faded. The Dow Jones Industrial A
Abbott Labs Expands into Cancer Diagnostics with Exact Sciences Acquisition
12:14pm, Thursday, 20'th Nov 2025
Abbott Labs (ABT) has acquired Exact Sciences (EXAS) for $105 per share in cash, a 56% premium over the previous stock price, valuing EXAS at $21 billion, or ap
Shareholder Alert: The Ademi Firm investigates whether Exact Sciences Corporation is obtaining a Fair Price for its Public Shareholders
11:45am, Thursday, 20'th Nov 2025
MILWAUKEE , Nov. 20, 2025 /PRNewswire/ -- The Ademi Firm is investigating Exact Sciences (NASDAQ: EXAS) for possible breaches of fiduciary duty and other violations of law in its recently announced t
